Guillain-Barré syndrome other diagnostic studies: Difference between revisions

Jump to navigation Jump to search
Priyamvada Singh (talk | contribs)
Priyamvada Singh (talk | contribs)
Line 4: Line 4:


==Overview==
==Overview==
'''Guillain-Barré syndrome''' ('''GBS''') is an acute, autoimmune, [[neuropathy|polyradiculoneuropathy]] affecting the [[peripheral nervous system]], usually triggered by an acute infectious process. It is included in the wider group of [[peripheral neuropathy|peripheral neuropathies]]. There are several types of GBS, but unless otherwise stated, GBS refers to the most common form, acute inflammatory demyelinating polyneuropathy (AIDP). It is frequently severe and usually exhibits as an ascending paralysis noted by weakness in the legs that spreads to the upper limbs and the face along with complete loss of deep tendon reflexes. With prompt treatment of [[plasmapheresis]] followed by [[immunoglobulins]] and supportive care, the majority of patients will regain full functional capacity. However, death may occur if severe pulmonary complications and [[dysautonomia]] are present.
'''Guillain-Barré syndrome''' ('''GBS''') is an acute, autoimmune, [[neuropathy|polyradiculoneuropathy]] affecting the [[peripheral nervous system]], usually triggered by an acute infectious process.
 
==Other diagnostic studies==
==Other diagnostic studies==
ECD is used almost every time to verify symptoms, but because of the acute nature of the disease, they may not become abnormal until after the first week of onset of signs and symptoms.
ECD is used almost every time to verify symptoms, but because of the acute nature of the disease, they may not become abnormal until after the first week of onset of signs and symptoms.

Revision as of 21:11, 24 February 2012

Guillain-Barré syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Guillain-Barré syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Guillain-Barré syndrome other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Guillain-Barré syndrome other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Guillain-Barré syndrome other diagnostic studies

CDC on Guillain-Barré syndrome other diagnostic studies

Guillain-Barré syndrome other diagnostic studies in the news

Blogs on Guillain-Barré syndrome other diagnostic studies

Directions to Hospitals Treating Guillain-Barré syndrome

Risk calculators and risk factors for Guillain-Barré syndrome other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editors-In-Chief: Priyamvada Singh, MBBS [2]

Overview

Guillain-Barré syndrome (GBS) is an acute, autoimmune, polyradiculoneuropathy affecting the peripheral nervous system, usually triggered by an acute infectious process.

Other diagnostic studies

ECD is used almost every time to verify symptoms, but because of the acute nature of the disease, they may not become abnormal until after the first week of onset of signs and symptoms. The following tests may be ordered:

  • Electrodiagnostics -
    • Electromyography (EMG)-EMG tests the electrical activity in muscles. It may show that nerves do not react properly to stimulation.
    • Nerve conduction study
      • (NCS) may show prolonged distal latencies, conduction slowing, conduction block, and temporal dispersion of compound action potential in demyelinating cases.
      • In primary axonal damage, the findings include reduced amplitude of the action potentials without conduction slowing.
      • Nerve motor action potentials may be decreased. Compound muscle action potential (CMAP) amplitude may be decreased.
      • The extent of decreased action potentials correlates with prognosis. Prolonged distal latencies may be present. Abnormal H-reflex may be noted.
      • Needle examination shows profuse and early denervation potentials also support the conclusion that there has been axonal injury

References

Template:WH Template:WS